Review
Venous and arterial thrombosis in COVID-19: An updated narrative review

https://doi.org/10.1016/j.jiph.2022.05.003Get rights and content
Under a Creative Commons license
open access

Abstract

Hospitalized patients with coronavirus disease 2019 (COVID-19), particularly those admitted to the intensive care unit (ICU) are at high risk of morbidity and mortality. Several observational studies have described hemostatic derangements and thrombotic complications in patients with COVID-19. The aim of this review article is to summarize the current evidence on pathologic findings, pathophysiology, coagulation and hemostatic abnormalities, D-dimer’s role in prognostication epidemiology and risk factors of thrombotic complications, and the role of prophylactic and therapeutic anticoagulation in patients with COVID-19. While existing evidence is limited in quality, COVID-19 appears to increase micro-and macro-vascular thrombosis rates in hospitalized and critically ill patients, which may contribute to the burden of disease. D-dimer can be used for risk stratification of hospitalized patients, but its role to guide anticoagulation therapy remains unclear. Evidence of higher quality is needed to address the role of therapeutic anticoagulation or high-intensity venous thromboembolism prophylaxis in COVID-19 patients.

Take-home points

  • The prevalence of venous thromboembolism (VTE) in hospitalized COVID-19 patients is high, therefore, clinicians should have a high index of suspicion.

  • The pathophysiology of thrombosis is likely related to a combination of SARS-CoV-2 direct endothelial injury and dysregulated inflammation causing coagulation activation.

  • The current evidence on the value of D-dimer guided therapy is limited.

  • The rate of VTE post-hospital discharge is very low, supporting the safety of current discharge practice without VTE prophylaxis in most patients.

  • The role of higher-intensity VTE prophylaxis or therapeutic anticoagulation in critically ill COVID-19 patients without documented or suspected VTE remains uncertain.

  • Therapeutic anticoagulation in hospitalized non-critically ill patients with COVID-19 may improve outcomes but more research is warranted.

Abbreviations

ACE-2
Angiotensin-Converting Enzyme-2
ARDS
acute respiratory distress syndrome
aPTT
activated partial thromboplastin time
BMI
body mass index
COVID-19
coronavirus disease 2019
CI
confidence interval
CrI
credible interval
DVT
deep venous thrombosis
DAD
diffuse alveolar damage
DIC
disseminated intravascular coagulation
ICU
intensive care unit
IQR
interquartile range
ELSO
Extracorporeal Life Support Organization
FDP
fibrin degradation products
HR
hazard ratio
PT
prolonged prothrombin time
PE
pulmonary embolism
NETs
neutrophil extracellular traps
OR
odds ratio
MD
mean difference
MI
myocardial infarction
UFH
unfractionated heparin
ROC
receiver operating curve
SIC
sepsis-induced coagulopathy

Keywords

Anticoagulation
COVID-19
Thrombosis
Venous thromboembolism prophylaxis
Critically ill
D-dimer level

Cited by (0)